Policy Watch: DEA Scheduling Actions on Synthetic Drugs — June 18, 2026
This update covers DEA scheduling synthetic drugs 2026 with six key regulatory actions impacting clinical research and cannabis-related therapies. The DEA placed several novel synthetic substances into Schedule I, affecting legal status and research…
Policy Watch: DEA Schedule I Placement of Synthetic Cannabinoids — June 17, 2026
The DEA synthetic cannabinoids Schedule I placement 2026 marks significant regulatory changes affecting clinical and legal frameworks. This update highlights the classification of several synthetic cannabinoids as Schedule I substances. These actions…
Policy Watch: DEA Synthetic Cannabinoids Schedule I Placement — June 16, 2026
The DEA synthetic cannabinoids schedule I placement 2026 updates highlight new regulatory actions affecting clinical practice. These changes impact research and legal status of synthetic cannabinoids. Clinicians should stay informed about these…
Policy Watch: 20 Regulatory Updates — June 06, 2026
The DEA synthetic cannabinoids Schedule I June 2026 updates highlight new regulatory actions on synthetic cannabinoids with high abuse potential. These changes affect clinical research and patient safety. Clinicians should stay informed about these…
Policy Watch: 20 Regulatory Updates — June 02, 2026
The schedules of controlled substances placement June 02 2026 report covers 20 regulatory updates affecting synthetic cannabinoids and opioids. These placements impact clinical research and patient care. Clinicians should stay informed on these…